Exploring Co-Diagnostics, Inc. (CODX) Investor Profile: Who’s Buying and Why?

Have you ever wondered who is investing in Co-Diagnostics, Inc. (CODX) and what their reasons are? As of December 31, 2024, a total of 49 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 6,072,063 shares. Institutional investors hold approximately 18.09% of the company's shares. With the share price experiencing a 70.44% decline from $1.14 on April 17, 2024, to $0.34 on April 16, 2025, understanding the dynamics of who is buying, selling, or holding onto CODX stock becomes crucial. Let's delve into the investor profile of Co-Diagnostics to uncover who the major players are and the factors influencing their investment decisions.

Co-Diagnostics, Inc. (CODX) Who Invests in [Company Name] and Why?

Understanding the investor profile of Co-Diagnostics, Inc. (CODX) involves examining the diverse range of individuals and institutions that hold its stock, as well as their motivations for investing. This includes identifying the primary types of investors, their investment strategies, and what factors attract them to Co-Diagnostics, Inc. (CODX). You can find more about Co-Diagnostics, Inc. (CODX) on this link: Co-Diagnostics, Inc. (CODX): History, Ownership, Mission, How It Works & Makes Money

Key Investor Types

The investor base of Co-Diagnostics, Inc. (CODX) can be broadly categorized into the following:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Retail investors may be attracted to Co-Diagnostics, Inc. (CODX) due to its growth potential or its position in the diagnostics market.
• Institutional Investors: These include entities such as mutual funds, pension funds, and insurance companies that invest on behalf of their clients. Institutional investors often have a longer-term investment horizon and may be drawn to Co-Diagnostics, Inc. (CODX) for its potential for long-term growth and stability.
• Hedge Funds: These are investment partnerships that use a variety of strategies to generate returns for their investors. Hedge funds may invest in Co-Diagnostics, Inc. (CODX) for short-term trading opportunities or based on specific investment theses.

Investment Motivations

Several factors may attract investors to Co-Diagnostics, Inc. (CODX):

• Growth Prospects: The diagnostics industry is expected to grow in the coming years, driven by factors such as an aging population and increasing demand for diagnostic testing. Investors may believe that Co-Diagnostics, Inc. (CODX) is well-positioned to capitalize on this growth.
• Market Position: Co-Diagnostics, Inc. (CODX) has developed a reputation for its innovative and accurate diagnostic tests. This market position may attract investors who believe that the company has a competitive advantage.

Investment Strategies

Investors in Co-Diagnostics, Inc. (CODX) may employ a variety of investment strategies, including:

• Long-Term Holding: Some investors may choose to hold Co-Diagnostics, Inc. (CODX) shares for the long term, believing in the company's long-term growth potential.
• Short-Term Trading: Other investors may engage in short-term trading, seeking to profit from fluctuations in the company's share price.
• Value Investing: Value investors may be attracted to Co-Diagnostics, Inc. (CODX) if they believe that the company's shares are undervalued by the market.

Understanding these diverse investor types, their motivations, and strategies is crucial for gaining a comprehensive view of the market dynamics surrounding Co-Diagnostics, Inc. (CODX).

Co-Diagnostics, Inc. (CODX) Institutional Ownership and Major Shareholders of Co-Diagnostics, Inc. (CODX)

Understanding the institutional ownership of Co-Diagnostics, Inc. (CODX) provides valuable insights into the company's stock price and overall strategy. Institutional investors, such as mutual funds, hedge funds, and pension funds, often hold significant stakes in publicly traded companies, and their investment decisions can have a substantial impact on market sentiment and stock performance.

Information on major shareholders and institutional ownership can often be found in a company's investor relations section or through financial data providers. These details can reveal trends in ownership, such as increases or decreases in institutional holdings, which may signal confidence or concern about the company's future prospects. Examining these ownership patterns can offer a deeper understanding of the market's perception of Co-Diagnostics, Inc. (CODX).

Here is a list of some of the top institutional investors in Co-Diagnostics, Inc. (CODX) and details about their shareholdings:

• Vanguard Group Inc.: As of March 31, 2024, Vanguard Group Inc. holds 1,478,864 shares, representing 4.74% ownership.
• BlackRock Fund Advisors: As of March 31, 2024, BlackRock Fund Advisors holds 1,014,537 shares, representing 3.25% ownership.
• State Street Global Advisors, Inc.: As of March 31, 2024, State Street Global Advisors, Inc. holds 624,991 shares, representing 2.00% ownership.
• Geode Capital Management LLC: As of March 31, 2024, Geode Capital Management LLC holds 507,981 shares, representing 1.63% ownership.
• Citadel Advisors LLC: As of March 31, 2024, Citadel Advisors LLC holds 397,631 shares, representing 1.27% ownership.

The table below summarizes the ownership data of these top institutional investors as of March 31, 2024:

Changes in institutional ownership can provide insights into the sentiment surrounding Co-Diagnostics, Inc. (CODX). For example:

• Increased Stakes: If institutional investors have been increasing their positions, it may indicate a positive outlook on the company's future performance.
• Decreased Stakes: Conversely, if institutional investors have been reducing their positions, it could suggest concerns about the company's prospects.

Reviewing the recent transactions of major holders can offer clues about the expectations of significant market participants. For instance, a large purchase by a well-respected investment firm might boost investor confidence, while a significant sell-off could raise red flags.

Institutional investors play a crucial role in the stock price and strategy of Co-Diagnostics, Inc. (CODX). Their actions can influence:

• Stock Price Volatility: Large trades by institutional investors can lead to increased stock price volatility.
• Company Strategy: Institutional investors may engage with company management to influence strategic decisions.
• Market Perception: The investment decisions of these large players can shape the overall market perception of the company.

Understanding these dynamics is essential for investors looking to make informed decisions about Co-Diagnostics, Inc. (CODX). For further insights into the company's values and objectives, consider exploring: Mission Statement, Vision, & Core Values of Co-Diagnostics, Inc. (CODX).

Co-Diagnostics, Inc. (CODX) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Co-Diagnostics, Inc. (CODX) provides valuable insights into the company's stability, growth potential, and market sentiment. A diverse investor base can offer a buffer against market volatility, while the actions of significant shareholders can influence stock movements and company strategy. As of April 2025, a mix of institutional, retail, and insider ownership characterizes Co-Diagnostics, Inc.’s shareholder composition.

As of December 31, 2024, 17.04% of Co-Diagnostics, Inc. (CODX) was owned by institutional shareholders. A total of 49 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 6,072,063 shares. This indicates moderate institutional interest. Retail investors hold a significant portion, accounting for 54.62%, while company insiders own 28.33% of the shares.

Here's a list of the top institutional holders as of December 31, 2024:

• Vanguard Group Inc: 1,778,182 shares
• Private Advisory Group LLC: 1,181,633 shares
• Renaissance Technologies Llc: 555,622 shares
• BlackRock, Inc.: 504,237 shares
• Geode Capital Management, Llc: 345,511 shares
• Bridgeway Capital Management, Llc: 272,900 shares
• Susquehanna International Group, Llp: 259,125 shares
• Bank Of New York Mellon Corp: 137,068 shares
• Kestra Advisory Services, Llc: 122,806 shares
• State Street Corp: 100,647 shares

These institutions can exert influence through their trading activity and, in some cases, through direct engagement with company management.

Key individual shareholders also play a crucial role. Brent Satterfield is the largest individual shareholder, owning 2.28 million shares, representing 6.78% of the company. As of early 2025, these shares were valued at approximately $789,430. The presence of significant insider ownership can align management's interests with those of other shareholders, fostering a focus on long-term value creation.

Recent trading activity indicates shifts in investor sentiment. For example, Private Advisory Group LLC increased its stake by adding 1,181,633 shares in Q4 2024, while Susquehanna International Group, LLP added 71,556 shares during the same period. Conversely, some institutions reduced their positions. Tracking these movements can provide insights into changing perceptions of Co-Diagnostics, Inc.'s prospects.

Recent insider activity shows that over the last 3 months, insiders have bought 882,499 shares and sold 174,463 shares, for a net activity of 708,036 shares. This suggests a positive sentiment among insiders.

The ownership structure impacts company decisions and stock movements. Major shareholders have the potential to influence corporate governance and strategic direction through voting rights and direct engagement with the board. Significant buying or selling activity by these investors can create upward or downward pressure on the stock price, affecting market sentiment and overall valuation.

For instance, Co-Diagnostics, Inc. faces a potential Nasdaq delisting due to non-compliance with the minimum bid price requirement, as its stock has traded below $1.00 for 30 consecutive business days. The company has until July 9, 2025, to meet the bid price requirement of closing at or above $1.00 for ten consecutive business days. If necessary, Co-Diagnostics may consider measures like a reverse stock split to regain compliance. These developments highlight the company's ongoing efforts to address regulatory challenges and improve its financial standing.

See more about Co-Diagnostics, Inc.'s financial health: Breaking Down Co-Diagnostics, Inc. (CODX) Financial Health: Key Insights for Investors

Co-Diagnostics, Inc. (CODX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating Co-Diagnostics, Inc. (CODX). Recent shifts in major shareholders' positions and overall market responses can significantly influence the stock's performance.

Based on the most recent information available, here's an overview of investor sentiment, market reactions, and analyst perspectives regarding Co-Diagnostics, Inc. (CODX):

• Investor Sentiment: The sentiment among major shareholders appears mixed. While some institutional investors have increased their stakes, others have reduced their holdings, reflecting differing views on the company's future prospects.
• Recent Market Reactions: The stock market's reaction to changes in ownership has been closely monitored. Significant acquisitions or disposals of shares by large investors often lead to increased trading volume and price volatility.
• Analyst Perspectives: Analysts' opinions on Co-Diagnostics, Inc. (CODX) vary. Some analysts highlight the company's potential for growth in the molecular diagnostics market, while others express concerns about competition and market saturation.

To further illustrate the dynamics of investor activity, consider the following hypothetical overview of significant shareholders:

These hypothetical examples demonstrate how different investor actions can lead to varied market reactions. Positive sentiment and increased holdings may drive the stock price up, while negative sentiment and decreased holdings can lead to a decline.

Keep in mind that analyst ratings and price targets are based on their independent analysis and models. These ratings are not guarantees of future performance but can offer valuable insights into market expectations. Always consider a range of perspectives and conduct thorough due diligence before making investment decisions.

For more insights into the financial health of the company, see: Breaking Down Co-Diagnostics, Inc. (CODX) Financial Health: Key Insights for Investors